Sponsor

Universitaetsklinikum Heidelberg AöR

Germany Im Neuenheimer Feld 672, Neuenheim, 69120 Heidelberg, Germany

About the sponsor

The sponsor is strongly involved in studies of multiple myeloma, acute lymphoblastic leukemia, non-Hodgkin lymphoma, follicular lymphoma, and AL amyloidosis, with a focus on treatment strategies for newly diagnosed, refractory, relapsed, and transplant-eligible disease.

Minimal residual disease assessment
Antibody-based therapy
CAR T-cell therapy
Maintenance treatment

Research activity also includes lymphoid diseases with emphasis on immune-targeted and cellular approaches.

About Specializations

Universitaetsklinikum Heidelberg AöR runs clinical trials in conditions such as Plasma cell myeloma, Glioma, Rheumatoid arthritis, Systemic sclerosis pulmonary, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

24 clinical trials

Rheumatoid arthritis+3

Recruiting

InvestigationalNo placebo

Safety Study of CD19.CAR T Cells in Patients with Autoimmune‑Associated Severe Interstitial Lung Fibrosis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Glioma

Recruiting

Registered drugNo placebo

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Tovorafenib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Ischaemic stroke

Recruiting

Registered drug

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Stress cardiomyopathy

Recruiting

Registered drug

Study on the Effects of Cyclosporine A in Patients with Takotsubo Syndrome

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ciclosporin
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Glioma

Recruiting

Registered drugNo placebo

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Acute lymphocytic leukaemia recurrent+1

Recruiting

InvestigationalNo placebo

Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
Sponsor:Universitaetsklinikum Heidelberg AöR